Sandra Aung

As Senior Vice President, Chief Clinical Development Officer, Dr. Aung is responsible for overseeing KEYNOTE-695, the Company's Phase 2b trial evaluating intratumoral delivery of its interleukin-12 (IL-12) based immunotherapy, TAVO™ (tavokinogene telseplasmid), in combination with intravenous KEYTRUDA® (pembrolizumab) in patients with unresectable, advanced melanoma, as well as overseeing OncoSec's additional clinical trials evaluating TAVO.